Shree Ganesh Remedies Limited has announced an Extraordinary General Meeting (EGM) scheduled for April 06, 2026 at 12:30 PM IST, to be conducted through video conferencing in compliance with regulatory guidelines. The pharmaceutical company has outlined two critical agenda items requiring shareholder approval and has published the official notice in newspapers on March 14, 2026.

Key Agenda Items

The EGM will address significant management appointments and related party transactions that are essential for the company's operational continuity.

Re-appointment of Whole-time Director

The primary agenda involves the re-appointment of Mr. Parth Chandulal Kothia (DIN: 08830608) as Whole-time Director and Chief Financial Officer. The proposed appointment details are:

Mr. Parth Kothia, aged 30 years, holds a B.Tech in Chemical Engineering and an MSc in Global Finance from Fordham University, USA. He has over five years of experience in business development for pharmaceutical intermediates and specialty chemicals, along with experience in the PE and venture capital industry in the USA. During FY 2024-25, he received remuneration of ₹ 96 lakhs plus ₹ 18 lakhs as incentive.

Related Party Transaction Approval

The second agenda item seeks approval for a related party transaction involving Mr. Gunjan Chandulal Kothia, son of Managing Director Mr. Chandulal Kothia and brother of Mr. Parth Kothia. The transaction details include:

Mr. Gunjan Kothia holds a Bachelor's degree in Chemical Engineering and a Master's degree in Science from the University of Leeds, United Kingdom. He brings valuable experience in research and development, having worked for two years in R&D in Organic Chemistry and five years in business development across pharmaceutical intermediates, specialty chemicals, and organic pigments.

E-voting and Meeting Procedures

The company has established comprehensive procedures for shareholder participation:

Voting Timeline

Shareholders can participate through video conferencing, with the facility available for 1,000 members on a first-come, first-served basis. This limitation excludes large shareholders (holding 2% or more), promoters, institutional investors, directors, and key managerial personnel, who can attend without restrictions.

Regulatory Compliance and Publication

The company has fulfilled its regulatory obligations by publishing the EGM notice in newspapers on March 14, 2026, as confirmed by Company Secretary and Compliance Officer Aditya Patel. The EGM notice has been prepared in accordance with:

• Section 108 of the Companies Act, 2013
• SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
• Various MCA circulars issued between 2020-2024
• SEBI circulars on e-voting procedures

CS Vishal Thawani, Practising Company Secretary and Partner of M/s. VTSN and Associates LLP, has been appointed as the Scrutinizer for conducting the remote e-voting process and venue voting system.

Corporate Governance Measures

The company emphasizes that both proposed transactions are conducted at arm's length and in the ordinary course of business. The Audit Committee and Board of Directors have recommended both resolutions after careful consideration of the candidates' qualifications, experience, and contribution to the company's growth initiatives.

Shareholders whose email addresses are not registered with the company or depositories are advised to update their contact information through their respective Depository Participants or by contacting the company's Registrar and Transfer Agent.

Shree Ganesh Remedies Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2025, following a Board of Directors meeting held on January 23, 2026. The pharmaceutical company, primarily engaged in bulk drug intermediates, reported mixed performance compared to the previous year.

Standalone Financial Performance

The company's standalone results for Q3FY26 showed revenue from operations of ₹2,110.68 lakhs, representing a decline from ₹2,705.28 lakhs in Q3FY25. Net profit after tax for the quarter was ₹309.62 lakhs, down from ₹543.34 lakhs in the corresponding quarter of the previous year.

Nine-Month Performance Analysis

For the nine-month period ended December 31, 2025, the company reported revenue from operations of ₹7,608.96 lakhs compared to ₹8,416.46 lakhs in the previous year. Net profit after tax for the nine-month period stood at ₹1,150.11 lakhs against ₹1,650.10 lakhs in the corresponding period of the previous year.

Consolidated Results

The consolidated financial results, which include the company's wholly-owned subsidiary SGRL USA INC, showed similar trends. For Q3FY26, consolidated net profit after tax was ₹309.09 lakhs compared to ₹542.35 lakhs in Q3FY25. The nine-month consolidated net profit was ₹1,149.16 lakhs against ₹1,647.82 lakhs in the previous year.

Cost Structure and Expenses

The company's cost of materials consumed for Q3FY26 was ₹894.67 lakhs compared to ₹1,023.30 lakhs in Q3FY25. Employee benefit expenses increased to ₹286.14 lakhs from ₹266.37 lakhs. Finance costs rose significantly to ₹73.59 lakhs from ₹37.51 lakhs in the corresponding quarter of the previous year.

Corporate Information

The results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on January 23, 2026. The financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013. The company operates primarily in the business of bulk drug intermediates, which constitutes a single reportable segment.